OSferionBiomaterials Corp.
Japanese orthopedic biomaterials and metal implant company dedicated to joint-preserving treatments and restoring patients' freedom of movement.
Last updated September 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
OSferionBiomaterials Corp. (OSB) is a Japanese medical device and biomaterials company headquartered in Shibuya-ku, Tokyo. Its business began on 1 October 2004 as Olympus Biomaterial Corporation, and it has since evolved through joint ventures, ownership changes and a 2025 renaming into its current form. The company researches, develops, manufactures and sells biomaterials such as artificial bone, metal implants designed to fit Japanese skeletal anatomy, and related treatment-support systems, with a focus on the spine, knee and ankle areas. OSB's mission is expressed as "Return to Active Life" — restoring patients' joy of moving freely. Its vision is to become the very "support of the body" by preserving and reconstructing native physical function, and its values are summarized as Openness, Speed and Breakthrough. A flagship area of activity is joint-preserving treatment for knee osteoarthritis, such as high tibial osteotomy, which can allow patients to return to high-impact sports like jogging or to physically demanding work. Beyond selling products, OSB emphasizes education for the spread of such treatments and collaborates with physicians on research to build clinical evidence. The company operates a Mishima factory and R&D center, a Shinagawa logistics center and a Fukuoka logistics center. As of 1 August 2025 it had 127 employees and capital of 100,000,000 yen. Its representative director and president is Manabu Ishikawa. Ownership has shifted over time: it became a wholly owned subsidiary of Olympus in August 2023, then changed parent to Polaris Capital Group in July 2024 through OrthoActiVolution Holdings, and in August 2025 merged with PTCJ-6O Holdings and adopted the OSferionBiomaterials name. In August 2026 it announced a business alliance with Japan Tissue Engineering Co., Ltd. to combine regenerative medicine with osteotomy for knee joint-preserving treatment.
History
OSferionBiomaterials Corp. traces its origins to September 2004, when Olympus Biomaterial Corporation was established. Business operations began on 1 October 2004. In September 2005 the company took over the Bone Ceram business from Sumitomo Osaka Cement Co., Ltd., expanding its biomaterials portfolio. In December 2006 it reached an agreement with Terumo Corporation concerning a joint business, and in January 2007 the Mishima Factory was completed. In April 2007 the company changed its name to Olympus Terumo Biomaterials Corporation, reflecting the joint venture structure. It obtained ISO 13485 certification in December 2007. During the following decade the company expanded its logistics and product capabilities: it opened the Shinagawa Logistics Center in July 2009 and the Fukuoka Logistics Center in May 2015. In June 2015 it began selling its own designed and developed metal implant products, marking a move beyond biomaterials into metal implants. In February 2016 it relocated its head office to Sasazuka, Shibuya-ku. It obtained MDSAP certification in March 2017, and in August 2020 the Mishima Factory and R&D Center obtained ISO 14001 certification. Ownership and structure changed significantly in the 2020s. In July 2023 the company transferred its collagen product development, manufacturing and sales business and its dental product sales business to GC Corporation. In August 2023 it became a wholly owned subsidiary of Olympus. In July 2024 its parent company changed to Polaris Capital Group Co., Ltd. through OrthoActiVolution Holdings株式会社. In August 2025 it merged with PTCJ-6O Holdings株式会社 and changed its name to OSferionBiomaterials株式会社. In August 2026 it announced a business alliance with Japan Tissue Engineering Co., Ltd. for knee joint-preserving treatment combining regenerative medicine and osteotomy. As of 1 August 2025 the company had 127 employees and capital of 100,000,000 yen, with Manabu Ishikawa as Representative Director and President.
Olympus Biomaterial Corporation established
Business operations commenced
Took over Bone Ceram business from Sumitomo Osaka Cement Co., Ltd.
Agreement with Terumo Corporation on joint business
Mishima Factory completed
Renamed to Olympus Terumo Biomaterials Corporation
Obtained ISO 13485 certification
Shinagawa Logistics Center opened
Fukuoka Logistics Center opened
Started sales of own designed and developed metal implant products
Products and positioning
A Japanese orthopedic biomaterials specialist focused on joint-preserving treatment, combining biomaterials, Japan-fit metal implants, education and clinical evidence-building to help patients return to active life.
Artificial bone biomaterials
Biomaterials for orthopedic applications, including artificial bone.
Metal implants for spine, knee and ankle
Metal implants designed to fit Japanese skeletal anatomy.
Treatment-support systems
Systems related to biomaterials and metal implants for surgical solutions.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/osferionbiomaterials · Editorial policy · How profiles are compiled